Sep. 2 at 4:12 PM
$AIFF
The Cognito HOPE trial isn’t necessarily “delayed” in any concerning sense. HOPE is a large, 670+ patient, 70-site pivotal Alzheimer’s trial involving 12 months of treatment and complex clinical, MRI and biomarker data. Cognito had guided to topline results around August/later summer—not a guaranteed release date.
After the final patient completes treatment, the work isn’t finished. Data must be collected from dozens of sites, cleaned, reconciled, locked and statistically analyzed before results can be responsibly released. For a pivotal trial potentially supporting an FDA De Novo submission, accuracy matters far more than hitting an informal calendar estimate.
Unless Cognito announces an actual problem, a short timing slip should not be confused with a negative trial result. The data—not a few extra days—will determine the outcome.
